Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1965 2
1966 6
1967 5
1968 8
1969 6
1970 11
1971 11
1972 9
1973 3
1974 5
1975 17
1976 16
1977 9
1978 16
1979 12
1980 13
1981 10
1982 17
1983 27
1984 16
1985 31
1986 46
1987 485
1988 1054
1989 1241
1990 1479
1991 1763
1992 1644
1993 1968
1994 2858
1995 3213
1996 3075
1997 3276
1998 3488
1999 3860
2000 4173
2001 4156
2002 4477
2003 5022
2004 5488
2005 5552
2006 4883
2007 4959
2008 4980
2009 5339
2010 5757
2011 6678
2012 7091
2013 8453
2014 11806
2015 14063
2016 15361
2017 16925
2018 18211
2019 19409
2020 20387
2021 20116
2022 16114
2023 15449
2024 22315
2025 30186
2026 4299

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

295,773 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean functional medicine clinic al trial (6,932 results)?
Clinical trial design in the era of precision medicine.
Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Fountzilas E, et al. Genome Med. 2022 Aug 31;14(1):101. doi: 10.1186/s13073-022-01102-1. Genome Med. 2022. PMID: 36045401 Free PMC article. Review.
Tumor and liquid biopsy genomic profiling and transcriptomic, immunomic, and proteomic interrogation can now all be leveraged to optimize therapy. Multiple new trial designs, including basket and umbrella trials, master platform trials, and N-of-1 patient-cen …
Tumor and liquid biopsy genomic profiling and transcriptomic, immunomic, and proteomic interrogation can now all be leveraged to optimize th …
Clinical Trial Design Innovations for Precision Medicine in Asthma.
Siddiqui S, Haf Davies E, Afshar M, Denlinger LC. Siddiqui S, et al. Adv Exp Med Biol. 2023;1426:395-412. doi: 10.1007/978-3-031-32259-4_17. Adv Exp Med Biol. 2023. PMID: 37464130
Severe asthma is a spectrum disorder with numerous subsets, many of which are defined by clinical history and a general predisposition for T2 inflammation. Most of the approved therapies for severe asthma have required clinical trial designs with population e …
Severe asthma is a spectrum disorder with numerous subsets, many of which are defined by clinical history and a general predispositio …
Small molecules, big impact: 20 years of targeted therapy in oncology.
Bedard PL, Hyman DM, Davids MS, Siu LL. Bedard PL, et al. Lancet. 2020 Mar 28;395(10229):1078-1088. doi: 10.1016/S0140-6736(20)30164-1. Lancet. 2020. PMID: 32222192 Review.
The identification of molecular targets and the growing knowledge of their cellular functions have led to the development of small molecule inhibitors as a major therapeutic class for cancer treatment. ...The future of small molecule inhibitors is promising as there is the …
The identification of molecular targets and the growing knowledge of their cellular functions have led to the development of small mo …
Bayesian cancer clinical trial designs with subgroup-specific decisions.
Thall PF. Thall PF. Contemp Clin Trials. 2020 Mar;90:105860. doi: 10.1016/j.cct.2019.105860. Epub 2019 Oct 31. Contemp Clin Trials. 2020. PMID: 31678411 Review.
Two illustrative applications are presented of Bayesian clinical trial designs that make adaptive subgroup-specific decisions based on elicited utilities of patient outcomes to quantify risk-benefit trade-offs. ...The second design is for a dose-finding trial …
Two illustrative applications are presented of Bayesian clinical trial designs that make adaptive subgroup-specific decisions …
Novel clinical trial designs emerging from the molecular reclassification of cancer.
Nikanjam M, Kato S, Allen T, Sicklick JK, Kurzrock R. Nikanjam M, et al. CA Cancer J Clin. 2025 May-Jun;75(3):243-267. doi: 10.3322/caac.21880. Epub 2025 Jan 22. CA Cancer J Clin. 2025. PMID: 39841128 Free PMC article. Review.
Consequently, oncology clinical trials have evolved from standard phase 1, 2, and 3 tissue-specific studies; to tissue-specific, biomarker-driven trials; to tissue-agnostic trials untethered from histology (all drug-centered designs); and, ultimately, …
Consequently, oncology clinical trials have evolved from standard phase 1, 2, and 3 tissue-specific studies; to tissue-specifi …
Personalized medicine in acromegaly: insights from the ACROFAST clinical trial.
Araujo-Castro M, Biagetti B, Navas-Moreno V, Bernarda-Iriarte M, Martínez-Hernández R, Valassi E, Puig-Domingo M, Marazuela M. Araujo-Castro M, et al. Expert Rev Endocrinol Metab. 2025 Nov;20(6):539-552. doi: 10.1080/17446651.2025.2561066. Epub 2025 Sep 29. Expert Rev Endocrinol Metab. 2025. PMID: 41020777 Review.
Moreover, we highlight the perspectives gained from the ACROFAST clinical trial, which has contributed with valuable insights into the clinical implementation of individualized therapeutic strategies. ...In addition, the application of artificial intelligence …
Moreover, we highlight the perspectives gained from the ACROFAST clinical trial, which has contributed with valuable insights …
New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P, Serghiou S, Ioannidis JPA. Janiaud P, et al. Cancer Treat Rev. 2019 Feb;73:20-30. doi: 10.1016/j.ctrv.2018.12.003. Epub 2018 Dec 11. Cancer Treat Rev. 2019. PMID: 30572165 Review.
We present and discuss the key features of the 30 eligible basket trials and 27 eligible umbrella trials. Only a minority of them are randomized (2 and 9, respectively), including three trials with adaptive randomization. Five of these trials have been …
We present and discuss the key features of the 30 eligible basket trials and 27 eligible umbrella trials. Only a minority of t …
Tumour heterogeneity.
Marte B. Marte B. Nature. 2013 Sep 19;501(7467):327. doi: 10.1038/501327a. Nature. 2013. PMID: 24048064 No abstract available.
Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.
Lin JA, He P. Lin JA, et al. Br Med Bull. 2015 Jun;114(1):17-27. doi: 10.1093/bmb/ldv011. Epub 2015 Apr 28. Br Med Bull. 2015. PMID: 25921239 Review.
INTRODUCTION: Recently, new clinical trial designs involving biomarkers have been studied and proposed in cancer clinical research, in the hope of incorporating the rapid growing basic research into clinical practices. SOURCES OF DATA: Journal articles …
INTRODUCTION: Recently, new clinical trial designs involving biomarkers have been studied and proposed in cancer clinical …
Beyond genomics.
Dollery CT. Dollery CT. Clin Pharmacol Ther. 2007 Oct;82(4):366-70. doi: 10.1038/sj.clpt.6100363. Clin Pharmacol Ther. 2007. PMID: 17851575 Review.
The sequencing of the human genome has already had an enormous impact on medicine, particularly with single-gene changes that predispose to a serious disease such as cystic fibrosis or the overexpression of Her2 in about one-third of breast cancers. ...
The sequencing of the human genome has already had an enormous impact on medicine, particularly with single-gene changes that predisp …
295,773 results
You have reached the last available page of results. Please see the User Guide for more information.